Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 1997

View Archived Issues

VM-201 preclinical data presented at AHA meeting

Xoma reports phase II results of Neuprex in trauma patients

Potent antineoplastic camptothecin derivative identified

MMP inhibitors in cardiovascular medicine

Fujisawa: HY 1998 highlights

Texas Biotechnology: Q3 1997 highlights

Onyx: Q3 1997 highlights

Synaptic: Q3 and nine-month highlights

Clinical safety and pharmacology of Vasoflux

Na+/H+ exchange inhibitors isolated from Indonesian medicinal plants

Selective collagenase 3 inhibitor shows promise for osteoarthritis

KE-298 suppresses MMP production in RA synoviocytes

First interim phase III safety results reported for OxSODrol

T-614, a new NSAID that appears to act as a lysosomal protease inhibitor

ImClone receives SBIR grant for angiogenesis research

Xoma develops potential new diagnostic tool for severe infections and sepsis

New vascular gene therapy company established with initial focus on VEGF-2

Roche in-licenses promising antiparkinsonian agent

Biomira: Q3 1997 highlights

nNOS inhibitor from Astra effective in animal models of stroke, ALS

Aradigm tests inhalation form of morphine in volunteers

Pfizer describes new PDE IV inhibitor for asthma

Teva: Q3 1997 highlights

Anti-CD45 MAb prolongs islet xenograft survival in diabetic mice

Ribozyme, Chiron initiate product development of RPI-4610

Allergan to market Penederm products in Central and South America

Peptide + ciclosporin combination improves renal allograft survival and function

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...